BrainStorm Cell Therapeutics Secures $400,000 in Premium Private Placement Financing to Support Neurodegenerative Treatments
On May 19, 2026, BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), renowned for its pioneering work in adult stem cell therapies aimed at neurodegenerative diseases, revealed that it has successfully entered into definitive agreements facilitating a private placement that will yield gross proceeds of $400,000. This funding is strategically important as the company prepares for a larger Phase 3b clinical trial of its innovative therapy, NurOwn®.
The recent private placements, priced at $0.95 per share, illustrate a remarkable 37.6% premium compared to the previous closing price of $0.69. As part of the arrangements, investors are offered 120% warrant coverage, with an exercise price set at $1.45 per share, valid for five years post-issuance. Two of these placements, garnering a total of $200,000, completed on May 11, 2026, while the remaining transaction concluded shortly after on May 18, 2026.
This financing moves forward on the back of BrainStorm’s earlier $2 million capital raise achieved in February 2026, where shares were priced at $0.60 with warrants available at $1.00. The increase in both share price and warrant strike price is viewed by the company as indicative of the market's growing confidence in BrainStorm’s risk profile and long-term viability.
Chaim Lebovits, President and CEO of BrainStorm, expressed that the confidence demonstrated by investors through this private placement highlights the robustness of their scientific foundation and the promising future of NurOwn®. He stated, "While the total capital needed for our Phase 3b Endurance trial is significantly larger, these premium placements serve the tactical objective of extending our operational runway and promoting regulatory progress without unnecessarily diluting current shareholders."
Lebovits further elaborated that as they approach the financial requirements necessary for the Endurance trial, BrainStorm is exploring numerous strategic avenues, including non-dilutive financing structures. He emphasizes the importance of securing this funding at a premium now to safeguard their capital structure and enhance their negotiating position with future potential investors.
The NurOwn® platform presents a promising and investigational therapeutic method targeting critical disease pathways relevant to neurodegenerative disorders. Utilizing autologous, bone marrow-derived mesenchymal stem cells (MSCs), the MSC-NTF cells are cultivated and differentiated under patented conditions that promote high neurotrophic factor (NTF) secretion levels. These autologous MSC-NTF cells have been engineered to deliver multiple NTFs and immunomodulatory cytokines precisely at the damage site to trigger a desired biological response, with the ultimate objective of slowing or stabilizing disease progression.
BrainStorm Cell Therapeutics Inc. is at the forefront of developing autologous adult stem cell therapies tailored to combat debilitating neurodegenerative conditions, primarily using its proprietary NurOwn® technology, which aims to modulate neuroinflammation and facilitate neuroprotection. The company’s flagship therapy, NurOwn®, which has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is currently in advanced stages being prepared for further clinical trials, including a Phase 3b trial based on a Special Protocol Assessment (SPA) agreement with the FDA.
BrainStorm’s the clinical program has enriched their understanding of ALS biology, including pharmacogenomic responses associated with various genotypes, with key biomarker data collected through multiple longitudinal evaluations. The company has disseminated its research outcomes via peer-reviewed journals, illustrating its commitment to scientific advancement.
Aside from its work on ALS, BrainStorm’s MSC-NTF cells have been tested in a Phase 2 open-label multicenter trial for progressive multiple sclerosis, supported by a grant from the National MS Society. The company is also advancing a proprietary allogeneic exosome-based platform designed for delivering therapeutic proteins and nucleic acids. Notably, BrainStorm has recently received a Notice of Allowance from the U.S. Patent and Trademark Office fortifying its intellectual property portfolio in this burgeoning segment of regenerative medicine.
To learn more about the advancements BrainStorm is making in the field of cell therapies, visit www.brainstorm-cell.com.
Transaction Highlights
The recent private placements, priced at $0.95 per share, illustrate a remarkable 37.6% premium compared to the previous closing price of $0.69. As part of the arrangements, investors are offered 120% warrant coverage, with an exercise price set at $1.45 per share, valid for five years post-issuance. Two of these placements, garnering a total of $200,000, completed on May 11, 2026, while the remaining transaction concluded shortly after on May 18, 2026.
This financing moves forward on the back of BrainStorm’s earlier $2 million capital raise achieved in February 2026, where shares were priced at $0.60 with warrants available at $1.00. The increase in both share price and warrant strike price is viewed by the company as indicative of the market's growing confidence in BrainStorm’s risk profile and long-term viability.
Management Insight
Chaim Lebovits, President and CEO of BrainStorm, expressed that the confidence demonstrated by investors through this private placement highlights the robustness of their scientific foundation and the promising future of NurOwn®. He stated, "While the total capital needed for our Phase 3b Endurance trial is significantly larger, these premium placements serve the tactical objective of extending our operational runway and promoting regulatory progress without unnecessarily diluting current shareholders."
Lebovits further elaborated that as they approach the financial requirements necessary for the Endurance trial, BrainStorm is exploring numerous strategic avenues, including non-dilutive financing structures. He emphasizes the importance of securing this funding at a premium now to safeguard their capital structure and enhance their negotiating position with future potential investors.
About NurOwn®
The NurOwn® platform presents a promising and investigational therapeutic method targeting critical disease pathways relevant to neurodegenerative disorders. Utilizing autologous, bone marrow-derived mesenchymal stem cells (MSCs), the MSC-NTF cells are cultivated and differentiated under patented conditions that promote high neurotrophic factor (NTF) secretion levels. These autologous MSC-NTF cells have been engineered to deliver multiple NTFs and immunomodulatory cytokines precisely at the damage site to trigger a desired biological response, with the ultimate objective of slowing or stabilizing disease progression.
Company Background
BrainStorm Cell Therapeutics Inc. is at the forefront of developing autologous adult stem cell therapies tailored to combat debilitating neurodegenerative conditions, primarily using its proprietary NurOwn® technology, which aims to modulate neuroinflammation and facilitate neuroprotection. The company’s flagship therapy, NurOwn®, which has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is currently in advanced stages being prepared for further clinical trials, including a Phase 3b trial based on a Special Protocol Assessment (SPA) agreement with the FDA.
BrainStorm’s the clinical program has enriched their understanding of ALS biology, including pharmacogenomic responses associated with various genotypes, with key biomarker data collected through multiple longitudinal evaluations. The company has disseminated its research outcomes via peer-reviewed journals, illustrating its commitment to scientific advancement.
Aside from its work on ALS, BrainStorm’s MSC-NTF cells have been tested in a Phase 2 open-label multicenter trial for progressive multiple sclerosis, supported by a grant from the National MS Society. The company is also advancing a proprietary allogeneic exosome-based platform designed for delivering therapeutic proteins and nucleic acids. Notably, BrainStorm has recently received a Notice of Allowance from the U.S. Patent and Trademark Office fortifying its intellectual property portfolio in this burgeoning segment of regenerative medicine.
To learn more about the advancements BrainStorm is making in the field of cell therapies, visit www.brainstorm-cell.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.